US20090076436A2 - Ocular implants with deployable structure - Google Patents

Ocular implants with deployable structure Download PDF

Info

Publication number
US20090076436A2
US20090076436A2 US11121584 US12158405A US2009076436A2 US 20090076436 A2 US20090076436 A2 US 20090076436A2 US 11121584 US11121584 US 11121584 US 12158405 A US12158405 A US 12158405A US 2009076436 A2 US2009076436 A2 US 2009076436A2
Authority
US
Grant status
Application
Patent type
Prior art keywords
apparatus
eye
implant
shape
members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11121584
Other versions
US20050192527A1 (en )
Inventor
Morteza Gharib
Hosheng Tu
Olav Bergheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaukos Corp
Original Assignee
Glaukos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00781Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/16Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for measuring intraocular pressure, e.g. tonometers

Abstract

An implant has a tubular member with an inlet configured to receive fluid from an anterior chamber of an eye, an outlet configured to deliver fluid from the inlet to a physiological outflow pathway of the eye, and a lumen therebetween configured for substantially free flow of the fluid and which generally defines a flow axis. At the outlet of the tubular member is a distal deployable portion that has a compacted position and an expanded position. The deployable portion is configured to expand in the physiological outflow pathway of the eye and moves transversely when transitioning between the compacted and expanded positions about a pivot axis which is substantially perpendicular to the flow axis.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation application of U.S. patent application Ser. No. 10/626,181, filed Jul. 24, 2003, entitled “Implant with Pressure Sensor for Glaucoma Treatment,” now U.S. Pat. No. 6,981,958, which is a continuation application of U.S. patent application Ser. No. 09/847,523, filed May 2, 2001, and entitled “Bifurcatable Trabecular Shunt for Glaucoma Treatment,” now U.S. Pat. No. 6,666,841, the entirety of each of which is hereby incorporated by reference.
  • BACKGROUND OF THE INVENTION
  • The present invention generally relates to medical devices and methods for reducing intraocular pressure in the animal eye. More particularly, the present invention relates to the treatment of glaucoma by permitting aqueous humor to flow out of the anterior chamber through a surgically implanted pathway.
  • The human eye is a specialized sensory organ capable of light reception and able to receive visual images. The trabecular meshwork serves as a drainage channel and is located in anterior chamber angle formed between the iris and the cornea. The trabecular meshwork maintains a balanced pressure in the anterior chamber of the eye by draining aqueous humor from the anterior chamber.
  • About two percent of people in the United States have glaucoma. Glaucoma is a group of eye diseases encompassing a broad spectrum of clinical presentations, etiologies, and treatment modalities. Glaucoma causes pathological changes in the optic nerve, visible on the optic disk, and it causes corresponding visual field loss, resulting in blindness if untreated. Lowering intraocular pressure is the major treatment goal in all glaucomas.
  • In glaucomas associated with an elevation in eye pressure (intraocular hypertension), the source of resistance to outflow is mainly in the trabecular meshwork. The tissue of the trabecular meshwork allows the aqueous humor (“aqueous”) to enter Schlemm's canal, which then empties into aqueous collector channels in the posterior wall of Schlemm's canal and then into aqueous veins, which form the episcleral venous system. Aqueous humor is a transparent liquid that fills the region between the cornea, at the front of the eye, and the lens. The aqueous humor is continuously secreted by the ciliary body around the lens, so there is a constant flow of aqueous humor from the ciliary body to the eye's front chamber. The eye's pressure is determined by a balance between the production of aqueous and its exit through the trabecular meshwork (major route) or uveal scleral outflow (minor route). The trabecular meshwork is located between the outer rim of the iris and the back of the cornea, in the anterior chamber angle. The portion of the trabecular meshwork adjacent to Schlemm's canal (the juxtacanilicular meshwork) causes most of the resistance to aqueous outflow.
  • Glaucoma is grossly classified into two categories: closed-angle glaucoma, also known as angle closure glaucoma, and open-angle glaucoma. Closed-angle glaucoma is caused by closure of the anterior chamber angle by contact between the iris and the inner surface of the trabecular meshwork. Closure of this anatomical angle prevents normal drainage of aqueous humor from the anterior chamber of the eye. Open-angle glaucoma is any glaucoma in which the angle of the anterior chamber remains open, but the exit of aqueous through the trabecular meshwork is diminished. The exact cause for diminished filtration is unknown for most cases of open-angle glaucoma. Primary open-angle glaucoma is the most common of the glaucomas, and it is often asymptomatic in the early to moderately advanced stage. Patients may suffer substantial, irreversible vision loss prior to diagnosis and treatment. However, there are secondary open-angle glaucomas which may include edema or swelling of the trabecular spaces (e.g., from corticosteroid use), abnormal pigment dispersion, or diseases such as hyperthyroidism that produce vascular congestion.
  • All current therapies for glaucoma are directed at decreasing intraocular pressure. Medical therapy includes topical ophthalmic drops or oral medications that reduce the production or increase the outflow of aqueous. However, these drug therapies for glaucoma are sometimes associated with significant side effects, such as headache, blurred vision, allergic reactions, death from cardiopulmonary complications, and potential interactions with other drugs. When drug therapy fails, surgical therapy is used. Surgical therapy for open-angle glaucoma consists of laser trabeculoplasty, trabeculectomy, and implantation of aqueous shunts after failure of trabeculectomy or if trabeculectomy is unlikely to succeed. Trabeculectomy is a major surgery that is widely used and is augmented with topically applied anticancer drugs, such as 5-flurouracil or mitomycin-C to decrease scarring and increase the likelihood of surgical success.
  • Approximately 100,000 trabeculectomies are performed on Medicare-age patients per year in the United States. This number would likely increase if the morbidity associated with trabeculectomy could be decreased. The current morbidity associated with trabeculectomy consists of failure (10-15%); infection (a life long risk of 2-5%); choroidal hemorrhage, a severe internal hemorrhage from low intraocular pressure, resulting in visual loss (1%); cataract formation; and hypotony maculopathy (potentially reversible visual loss from low intraocular pressure).
  • For these reasons, surgeons have tried for decades to develop a workable surgery for the trabecular meshwork.
  • The surgical techniques that have been tried and practiced are goniotomy/trabeculotomy and other mechanical disruptions of the trabecular meshwork, such as trabeculopuncture, goniophotoablation, laser trabecular ablation, and goniocurretage. These are all major operations and are briefly described below.
  • Goniotomy/Trabeculotomy: Goniotomy and trabeculotomy are simple and directed techniques of microsurgical dissection with mechanical disruption of the trabecular meshwork. These initially had early favorable responses in the treatment of open-angle glaucoma. However, long-term review of surgical results showed only limited success in adults. In retrospect, these procedures probably failed due to cellular repair and fibrosis mechanisms and a process of “filling in.” Filling in is a detrimental effect of collapsing and closing in of the created opening in the trabecular meshwork. Once the created openings close, the pressure builds back up and the surgery fails.
  • Trabeculopuncture: Q-switched Neodynium (Nd) YAG lasers also have been investigated as an optically invasive technique for creating full-thickness holes in trabecular meshwork. However, the relatively small hole created by this trabeculopuncture technique exhibits a filling-in effect and fails.
  • Goniophotoablation/Laser Trabecular Ablation: Goniophotoablation is disclosed by Berlin in U.S. Pat. No. 4,846,172 and involves the use of an excimer laser to treat glaucoma by ablating the trabecular meshwork. Additionally, an Erbium:YAG laser was used to create full-thickness holes through trabecular meshwork in a primate model and a limited human clinical trial at the University of California, Irvine. (Hill et al., Lasers in Surgery and Medicine 11:341-346, 1991). Although morbidity was zero in both trials, success rates did not warrant further human trials. Failure was again from filling in of surgically created defects in the trabecular meshwork by repair mechanisms.
  • Goniocurretage: This is an ab interno (from the inside), mechanically disruptive technique that uses an instrument similar to a cyclodialysis spatula with a microcurrette at the tip. Initial results were similar to trabeculotomy: it failed due to repair mechanisms and a process of filling in.
  • Although trabeculectomy is the most commonly performed filtering surgery, viscocanulostomy (VC) and non-penetrating trabeculectomy (NPT) are two new variations of filtering surgery. These are ab externo (from the outside), major ocular procedures in which Schlemm's canal is surgically exposed by making a large and very deep scleral flap. In the VC procedure, Schlemm's canal is cannulated and viscoelastic substance injected (which dilates Schlemm's canal and the aqueous collector channels). In the NPT procedure, the inner wall of Schlemm's canal is stripped off after surgically exposing the canal.
  • Trabeculectomy, VC, and NPT involve the formation of an opening or hole under the conjunctiva and scleral flap into the anterior chamber, such that aqueous humor is drained onto the surface of the eye or into the tissues located within the lateral wall of the eye. These surgical operations are major procedures with significant ocular morbidity. When trabeculectomy, VC, and NPT are thought to have a low chance for success, a number of implantable drainage devices have been used to ensure that the desired filtration and outflow of aqueous humor through the surgical opening will continue. The risk of placing a glaucoma drainage device also includes hemorrhage, infection, and diplopia (double vision).
  • Examples of implantable shunts and surgical methods for maintaining an opening for the release of aqueous humor from the anterior chamber of the eye to the sclera or space beneath the conjunctiva have been disclosed in, for example, U.S. Pat. No. 6,059,772 to Hsia et al., and U.S. Pat. No. 6,050,970 to Baerveldt.
  • All of the above embodiments and variations thereof have numerous disadvantages and moderate success rates. They involve substantial trauma to the eye and require great surgical skill in creating a hole through the full thickness of the sclera into the subconjunctival space. The procedures are generally performed in an operating room and have a prolonged recovery time for vision.
  • The complications of existing filtration surgery have prompted ophthalmic surgeons to find other approaches to lowering intraocular pressure.
  • The trabecular meshwork and juxtacanilicular tissue together provide the majority of resistance to the outflow of aqueous and, as such, are logical targets for surgical removal in the treatment of open-angle glaucoma. In addition, minimal amounts of tissue are altered and existing physiologic outflow pathways are utilized.
  • As reported in Arch. Ophthalm. (2000) 118:412, glaucoma remains a leading cause of blindness, and filtration surgery remains an effective, important option in controlling the disease. However, modifying existing filtering surgery techniques in any profound way to increase their effectiveness appears to have reached a dead end. The article further states that the time has come to search for new surgical approaches that may provide better and safer care for patients with glaucoma.
  • Therefore, there is a great clinical need for the treatment of glaucoma by a method that is faster, safer, and less expensive than currently available modalities.
  • SUMMARY OF THE INVENTION
  • Glaucoma surgical morbidity would greatly decrease if one were to bypass the focal resistance to outflow of aqueous only at the point of resistance, and to utilize remaining, healthy aqueous outflow mechanisms. This is in part because episcleral aqueous humor exerts a backpressure that prevents intraocular pressure from going too low, and one could thereby avoid hypotony. Thus, such a surgery would virtually eliminate the risk of hypotony-related maculopathy and choroidal hemorrhage. Furthermore, visual recovery would be very rapid, and the risk of infection would be very small, reflecting a reduction in incidence from 2-5% to about 0.05%.
  • Techniques performed in accordance with the aspects of the invention may be referred to generally as “trabecular bypass surgery.” Advantages of this surgery include lowering intraocular pressure in a manner which is simple, effective, disease site-specific, and can potentially be performed on an outpatient basis.
  • Trabecular bypass surgery (TBS) creates an opening, a slit, or a hole through trabecular meshwork with minor microsurgery. TBS has the advantage of a much lower risk of choroidal hemorrhage and infection than prior techniques, and it uses existing physiologic outflow mechanisms. In some aspects, this surgery can potentially be performed under topical or local anesthesia on an outpatient basis with rapid visual recovery. To prevent “filling in” of the hole, a biocompatible elongated device is placed within the hole and serves as a stent. U.S. patent application Ser. No. 09/549,350, filed Apr. 14, 2000, the entire contents of which are incorporated herein by reference, discloses trabecular bypass surgery.
  • In accordance with some embodiments, a trabecular shunt for transporting aqueous humor is provided. The trabecular shunt includes a hollow, elongate tubular element, having an inlet section and an outlet section. The outlet section includes two bifurcatable segments or elements, adapted to be positioned and stabilized inside Schlemm's canal.
  • In one aspect, the trabecular shunt is placed inside a delivery apparatus. When the trabecular shunt is deployed from the delivery apparatus into the eye, the two bifurcatable elements of the outlet section bifurcate in substantially opposite directions. In one embodiment, a deployment mechanism within the delivery apparatus includes a push-pull type plunger.
  • In another aspect, a delivery applicator may be placed inside a lumen of the hollow, elongate tube of the trabecular shunt. The delivery applicator may include a deployment mechanism for causing the two bifurcatable elements of the outlet section to bifurcate. In some embodiments, the delivery applicator may be a guidewire, an expandable basket, an inflatable balloon, or the like.
  • In accordance with another feature, at least one of the two bifurcatable elements is made of a shape-memory material, such as Nitinol or a shape-memory plastic. The shape-memory material has a preshape and a shape-transition temperature, such that the shape-memory trabecular shunt bifurcates to its preshape when it is heated to above the shape-transition temperature. The preshape of the two bifurcatable elements material may be at an angle with respect to the inlet section, preferably between about 70 degrees and about 110 degrees. An external heat source may be provided, which is adapted for heating the shape-memory material to above the shape-transition temperature of the shape-memory material.
  • In some aspects, the trabecular shunt may be made of one or more of the following materials: polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polyimide, polysilison, silicone, polyurethane, Nylon™, polypropylene, hydroxyapetite, precious metal, Nitinol, stainless steel, biodegradable materials, and biocompatible materials. Further, the outlet section of the trabecular shunt may be configured as a coil, mesh, spiral, or other appropriate configuration as will apparent to those of skill in the art. Further, the outlet section of the trabecular shunt may be porous, semi-permeable, fishbone, and/or of a continuous, solid form. The outlet section of the trabecular shunt may have a cross-sectional shape that is elliptical (e.g., oval), round, circular, D-shape, semi-circular, or irregular (asymmetrical) shape.
  • In one embodiment, at least one of the two bifurcatable elements has a tapered distal end, adapted for insertion ease. The trabecular shunt may have its surface coated with a coating material selected from one or more of the following: polytetrafluoroethylene (e.g., Teflon™), polyimide, hydrogel, heparin, hydrophilic compound, anti-angiogenic factor, anti-proliferative factor, therapeutic drugs, and the like. The surface coating material may also provide a mechanism for site-specific therapies.
  • In one embodiment, the device may include a flow-restricting member for restricting at least one component in fluid. The flow-restricting member may be a filter comprising one or more filtration materials selected from the following: expanded polytetrafluoroethylene, cellulose, ceramic, glass, Nylon, plastic, fluorinated material, or the like. The flow-restricting member may advantageously be a filter selected from the following group of filter types: hydrophobic, hydrophilic, membrane, microporous, and non-woven. The flow-restricting member acts to limit or prevent the reflux of any undesired component or contaminant of blood, such as red blood cells or serum protein, from the aqueous veins into the anterior chamber. It is useful to restrict one or more of the following components or contaminants: platelets, red blood cells, white blood cells, viruses, bacteria, antigens, and toxins.
  • The trabecular shunt may include a pressure sensor for measuring the pressure of the anterior chamber of an eye of a patient. The pressure sensor may further include an electromagnetic (e.g., radiofrequency) transmitter, for wirelessly transmitting pressure measurements to a pressure receiver outside the patient's body.
  • Among the advantages of trabecular bypass surgery is its simplicity. The microsurgery may potentially be performed on an outpatient basis with rapid visual recovery and greatly decreased morbidity. There is a lower risk of infection and choroidal hemorrhage, and there is a faster recovery, than with previous techniques.
  • Further features and advantages of the invention will become apparent to one of skill in the art in view of the Detailed Description that follows, when considered together with the attached drawings and claims.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a sagittal sectional view of an eye.
  • FIG. 2 is a cross-sectional view of the anterior chamber of an eye.
  • FIG. 3A is an side elevational view of a glaucoma device.
  • FIG. 3B is an end cross-sectional view through plane 1-1 of FIG. 3A.
  • FIG. 4A illustrates the trabecular shunt of FIG. 3A at a semi-deployment state.
  • FIG. 4B is an end cross-sectional view of section 2-2 of FIG. 4A.
  • FIG. 5A illustrates the trabecular shunt of FIG. 3A in a deployed state.
  • FIG. 5B is an end cross-sectional view of the trabecular shunt, section 3-3 of FIG. 5A.
  • FIG. 5C is an end cross-sectional view of a bifurcatable segment, section 4-4 of FIG. 5A.
  • FIG. 6 is a side cross-sectional view of the trabecular shunt.
  • FIG. 7A is a side cross-sectional view of an alternate embodiment of the trabecular shunt.
  • FIG. 7B is a side cross-sectional view of the trabecular shunt of FIG. 7A in a partially deployed state.
  • FIG. 8 is a perspective view of the trabecular shunt placed inside Schlemm's canal.
  • DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
  • FIGS. 1 to 8 illustrate an apparatus for the treatment of glaucoma by trabecular bypass surgery.
  • FIG. 1 is a sagittal sectional view of an eye 10, while FIG. 2 is a close-up view, showing the relative anatomical locations of trabecular meshwork 21, the anterior chamber 20, and Schlemm's canal 22. Thick collagenous tissue known as sclera 11 covers the entire eye 10 except that portion covered by the cornea 12. The cornea 12 is a thin transparent tissue that focuses and transmits light into the eye and through the pupil 14, which is the circular hole in the center of the iris 13 (colored portion of the eye). The cornea 12 merges into the sclera 11 at a juncture referred to as the limbus 15. The ciliary body 16 extends along the interior of the sclera 11 and is coextensive with the choroid 17. The choroid 17 is a vascular layer of the eye 10, located between the sclera 11 and retina 18. The optic nerve 19 transmits visual information to the brain and is the anatomic structure that is progressively destroyed by glaucoma.
  • The anterior chamber 20 of the eye 10, which is bound anteriorly by the cornea 12 and posteriorly by the iris 13 and lens 26, is filled with aqueous humor (“aqueous”). Aqueous is produced primarily by the ciliary body 16, then moves anteriorly through the pupil 14 and reaches the anterior chamber angle 25, formed between the iris 13 and the cornea 12. In a normal eye, the aqueous is removed from the anterior chamber 20 through the trabecular meshwork 21. Aqueous passes through trabecular meshwork 21 into Schlemm's canal 22 and thereafter through the aqueous veins 23, which merge with blood-carrying veins and into the systemic venous circulation. Intraocular pressure is maintained by the intricate balance between secretion and outflow of the aqueous in the manner described above. Glaucoma is, in most cases, characterized by the excessive buildup of aqueous humor in the anterior chamber 20, which leads to an increase in intraocular pressure. Fluids are relatively incompressible, and pressure is directed relatively equally throughout the eye.
  • As shown in FIG. 2, the trabecular meshwork 21 is adjacent a small portion of the sclera 11. Traditional procedures that create a hole or opening for implanting a device through the tissues of the conjunctiva 24 and sclera 11 involve extensive surgery, as compared to surgery for implanting a device which ultimately resides entirely within the confines of the sclera 11 and cornea 12, as is performed in accordance with one aspect. A device 31 for establishing an outflow pathway, positioned through the trabecular meshwork 21, is illustrated in FIG. 8.
  • In one embodiment, a method of placing a trabecular shunt into an opening through trabecular meshwork, the method comprises advancing and positioning a trabecular shunt having two distal bifurcatable elements through the opening. In a further embodiment, a method of placing a trabecular shunt into an opening through diseased trabecular meshwork for transporting aqueous humor at the level of the trabecular meshwork and using an existing outflow pathway, the method comprises advancing and positioning a trabecular shunt having a pressure sensor for measuring the pressure of the anterior chamber of the eye through the opening. In one embodiment, the method may further comprise transmitting the measured pressure to a pressure receiver outside the body of the patient.
  • FIG. 3A shows an embodiment of the trabecular shunt 31. The trabecular shunt may comprise a biocompatible material, such as medical grade silicone, trade name Silastic, available from Dow Corning Corporation of Midland, Mich.; or polyurethane, trade name Pellethane, also available from Dow Corning Corporation. In some embodiments, other biocompatible materials (biomaterials) may be used, such as polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polyimide, polysilison, silicone, polyurethane, Nylon, polypropylene, hydroxyapetite, precious metal, Nitinol, stainless steel, or any mixture of these or other biocompatible materials. In a further embodiment, the trabecular shunt may comprise a composite biocompatible material, with a surface made of one or more of the above-mentioned biomaterials, and the surface is coated by a material selected from Teflon, polyimide, hydrogel, heparin, hydrophilic compound, anti-angiogenic factor, anti-proliferative factor, therapeutic drugs, and the like. Suitable anti-angiogenic or anti-proliferative factors may be selected from, for example, protamine, heparin, steroids, anti-invasive factor, retinoic acids and derivatives thereof, and paclitaxel or its analogues or derivatives thereof.
  • The main purpose of the trabecular shunt is for transporting aqueous humor at the level of the trabecular meshwork and partially using existing the outflow pathway for aqueous humor, i.e., utilizing the entire outflow pathway except for the trabecular meshwork, which is bypassed by the trabecular shunt 31. In this manner, aqueous humor is transported into Schlemm's canal and subsequently into the aqueous collectors and the aqueous veins so that the intraocular pressure is properly maintained within a therapeutic range.
  • In one embodiment, the trabecular shunt 31 comprises a hollow, elongated tubular element having an inlet section 32 and an outlet section 33, wherein the outlet section 33 may comprise two bifurcatable elements 34, 35 that are adapted to be bifurcated, positioned, and stabilized inside Schlemm's canal. The hollow elongated tubular element may comprise at least one lumen 36 for transporting aqueous from the anterior chamber 20 of an eye to the Schlemm's canal 22. A “bifurcatable” segment is defined as a segment, or components thereof, that can change direction away or evert from a reference axis. The “bifurcating” operation may be achieved by mechanical forces and/or through the shape-memory property of a material.
  • For stabilization purposes, the outer surface of the outlet section 33 may comprise a stubbed surface, ribbed surface, surface with pillars, textured surface, or the like. The outer surface of the trabecular shunt 31 is biocompatible and tissue-compatible so that the interaction between the outer surface of the shunt and the surrounding tissue of Schlemm's canal is minimal, and inflammation is reduced. FIG. 3B shows an end cross-sectional view of section 1-1 of FIG. 3A. Each bifurcatable segment 34, 35 has its own end configuration. At least one of the two bifurcatable elements has a tapered distal end adapted for insertion ease. The two bifurcatable elements 34, 35 are secured to the inlet section 32 at a joint 37. In an alternate embodiment, at least a slit 38, or scalloping, within the two bifurcatable elements 34, 35 may be located near the joint 37 for stress release when the two bifurcatable elements are bifurcated in two substantially opposite directions. Other stress-releasing mechanisms may also be utilized so as to make the bifurcation operation of the bifurcatable elements safe and effective. The outlet section 33 of the trabecular shunt 31 may possess a cross-sectional shape selected from the following: oval shape, round shape, circular shape, D-shape, semi-circular shape, irregular shape, or random shape.
  • In another preferred embodiment, the trabecular shunt 31 may comprise a flow-restricting element for restricting at least one component in fluid, wherein the flow-restricting element may be a filter selected from a group of filtration materials comprising expanded polytetrafluoroethylene, cellulose, ceramic, glass, Nylon, plastic, and fluorinated material. Furthermore, the flow-restricting element may be a filter selected from a group of filter types comprising a hydrophobic filter, hydrophilic filter, membrane filter, microporous filter, non-woven filter, and the like. Components in blood that may be restricted by the flow-restricting element can include the following: platelet, red blood cell, white blood cell, virus, antigen, serum protein, and toxin. The flow-restricting element may also be in the form of, for example, a check valve, a slit valve, a micropump, a semi-permeable membrane, and the like. The purpose of the flow-restricting element is to keep an undesired foreign material from back flowing into the anterior chamber.
  • FIG. 4A shows the trabecular shunt of FIG. 3A in a semi-deployed state, while FIG. 4B shows an end cross-sectional view of section 2-2 of FIG. 4A. In one embodiment for shunt delivery, the trabecular shunt 31 is placed inside a hollow delivery apparatus 45. A delivery apparatus 45 comprises a distal end 47, wherein the two bifurcatable elements 34, 35 of the outlet section are self-bifurcatable in substantially two opposite directions when the trabecular shunt 31 is deployed out of the delivery apparatus 45. The slit 38 at the two bifurcatable elements 34, 35 comprises the separating regions 43A and 43B. The delivery apparatus 45 may comprise a deployment mechanism for deploying the trabecular shunt out of the delivery apparatus. In one embodiment, the deployment mechanism is a plunger. The delivery mechanism may be located at the handle of the delivery apparatus for deploying the trabecular shunt.
  • FIG. 5A shows the trabecular shunt of FIG. 3A at a deployed state. As the plunger is continuously pushed ahead, and the distal end 47 of the delivery apparatus 45 retreats, the two bifurcatable elements 34, 35 continue to deploy in two substantially opposite directions. This may be accomplished by precontracting the two bifurcatable elements within the delivery apparatus before the delivery state. When the distal end of the delivery apparatus withdraws beyond the joint point 37 located between the inlet section 32 and the outlet section, the two bifurcatable elements are fully deployed with their separating regions 43A, 43B apart from each other. The outlet section of the preferred trabecular shunts may be made of a material form selected from a group comprising coil form, mesh form, spiral form, porous form, semi-permeable form, fishbone form (i.e., having interlocking splines and/or fenestrations in a side wall, as illustrated in FIG. 7A), continuous solid form, or may be made from any form that is effective and appropriate to evert the bifurcatable elements to be at one or more angles with respect to a reference axis of the inlet section.
  • FIG. 5B shows an end cross-sectional view of the trabecular shunt, section 3-3 of FIG. 5A, while FIG. 5C shows an end cross-sectional view of a bifurcatable segment, section 4-4 of FIG. 5A. The original outer contour of the trabecular shunt 31 is illustrated by a dashed line 49 in FIG. 5B. The lumen 36 of the hollow elongated tubular element is for aqueous to flow through the trabecular shunt. The shape of the end cross-section 35 is to provide a stenting capability when the elements are placed inside Schlemm's canal. The semicircular end cross-section of the bifurcatable elements 34, 35 allows aqueous to freely flow into aqueous collector channels in the external wall of Schlemm's canal.
  • FIG. 6 shows another preferred embodiment of the trabecular shunt. A delivery applicator 52 may be placed inside a lumen of the hollow elongated tubular element, wherein the delivery applicator comprises a deployment mechanism for causing the two bifurcatable elements 34, 35 of the outlet section to move part from each other. The delivery applicator may be selected from a group consisting of a guidewire, an expandable basket, an inflatable balloon, or other expanding mechanism. In one embodiment, a delivery applicator 52 with an expandable basket comprises a plurality of expandable members 54A, 54B, 54C, 54D that all securely joined at a proximal joint 55A and at a distal joint point 55B. A distal end of a push-pull type wire 51 is also joined at the distal joint point 55B. The proximal joint 55A is located at the distal end of a compact guidewire 53 of the delivery applicator. Therefore, by pulling the push-pull wire 51 of the delivery applicator toward the operator, each of the expandable members 54A, 54B, 54C, 54D expand radially outwardly so as to effect the outward pushing action for the bifurcatable elements 34, 35.
  • U.S. Pat. No. 6,077,298 and U.S. patent application Ser. No. 09/452,963, filed Dec. 2, 1999, both of which are incorporated herein by reference in their entirety, disclose a medical device made of shape-memory Nitinol having a shape-transition temperature. In a further embodiment, a trabecular shunt comprises a hollow elongated tubular element having an inlet section and an outlet section, wherein the outlet section comprises two bifurcatable elements adapted to be positioned and stabilized inside Schlemm's canal. At least one of the two bifurcatable elements may be made of a shape-memory material such as shape-memory Nitinol or shape-memory plastic material. In a preferred embodiment, the shape-memory Nitinol has a preshape and a shape-transition temperature, wherein the shape-memory Nitinol bifurcates to its preshape when the shape-memory Nitinol is heated to above the shape-transition temperature, the preshape of the shape-memory Nitinol being at an angle with respect to the inlet section.
  • The shape-transition temperature for the shape-memory Nitinol is preferably between about 39° C. and about 90° C. The shape-transition temperature is more preferred between about 39° C. and 45° C. so as to minimize tissue damage. The angle is preferably between about 70 degrees and about 110 degrees so as to conform to the contour of Schlemm's canal. An external heat source may be provided and adapted for heating the shape-memory Nitinol to above the shape-transition temperature of the shape-memory Nitinol. Examples of such external heat sources include a heating pad, a warm cloth, a bag of warm water, remotely deliverable heat, electromagnetic field, and the like. In another embodiment, the shape-memory Nitinol may be embedded within a biocompatible material selected from, for example, silicone, polyurethane, porous material, expanded polytetrafluoroethylene, semi-permeable membrane, elastomer, and mixture of the biocompatible material thereof. In general, the bifurcatable elements are relatively flexible and soft so that they do not impart undesired force or pressure onto the surrounding tissue during and after the deployment state.
  • For illustration purposes, a fishbone-type outlet section is shown to render the bifurcatable elements flexible and soft during the deployment state. FIG. 7A shows an embodiment of the trabecular shunt. The trabecular shunt comprises a plurality of fishbones and their intermediate spacing, such as the fishbones 61A, 61B with a spacing 62A and the fishbones 61C, 61D with a spacing 62B. A delivery apparatus 45 may be used to deliver the self-bifurcatable elements 34, 35 having fishbones configuration.
  • FIG. 7B shows the trabecular shunt of FIG. 7A in a semi-deployed state. As the distal end 47 of the delivery apparatus 45 is pulled away from the distal end 39 of the shunt 31, the self-bifurcatable elements 34, 35 tend to deploy to two opposite directions. In the meantime, the spacing 62B between the two fishbones 61C and 61D starts to expand and enlarge so that minimal stress is exerted on the deployed bifurcated portion of the bifurcatable elements 34, 35.
  • The trabecular shunt may have a length between about 0.5 mm to over a few millimeters. The outside diameter of the trabecular shunt may range from about 30 μm to about 500 μm or more. The lumen diameter is preferably in the range of about 20 μm to about 150 μm, or larger. The trabecular shunt may have a plurality of lumens to facilitate multiple-channel flow. The outlet section may be curved or angled at an angle between about 30 degrees to about 150 degrees, and preferably at about 70 degrees to about 110 degrees, with reference to the inlet section 32.
  • FIG. 8 is a perspective view illustrating the device 31 positioned within the tissue of an eye 10. A hole or opening is created through the diseased trabecular meshwork 21. The outlet section of the device 31 is inserted into the hole, wherein the inlet section is exposed to the anterior chamber 20 while the outlet section is positioned at about an exterior surface 3 of the diseased trabecular meshwork 21. In a further embodiment, the outlet section may enter into Schlemm's canal or other existing outflow pathways. A device as shown in FIG. 3 may be successfully used to maintain the opening through diseased trabecular meshwork.
  • In one embodiment, means for forming a hole/opening in the trabecular mesh 21 may comprise using a microknife, a pointed guidewire, a sharpened applicator, a screw shaped applicator, an irrigating applicator, or a barbed applicator. Alternatively, the trabecular meshwork may be dissected off with an instrument similar to a retinal pick or microcurrette. The opening may alternately be created by retrograde fiberoptic laser ablation.
  • In a preferred embodiment of the trabecular meshwork surgery, the patient is placed in the supine position, prepped, draped and anesthesia obtained. In one embodiment, a small (generally less than 1-mm) self-sealing incision is made. Through the cornea opposite the shunt placement site, an incision is made in the trabecular meshwork with an irrigating knife. The shunt is then advanced through the corneal incision across the anterior chamber held in a delivery apparatus or delivery applicator under gonioscopic (lens) or endoscopic guidance. The apparatus or applicator is withdrawn from the patient and the surgery is concluded. The delivery apparatus or applicator may be within a size range of 20 to 40 gauge, and preferably about 30 gauge.
  • In a further embodiment, a method for increasing aqueous humor outflow in an eye of a patient to reduce intraocular pressure therein, the method comprises: (a) creating an opening in trabecular meshwork using a knife or laser, etc; (b) inserting a trabecular shunt into the opening, such as by using a delivery device, wherein the trabecular shunt comprises a hollow elongated tubular element having an inlet section and an outlet section, and wherein the outlet section comprises two bifurcatable elements adapted to be positioned and stabilized inside Schlemm's canal; and (c) bifurcating the two bifurcatable elements to two opposing directions.
  • The method may further comprise placing the trabecular shunt inside a delivery apparatus, wherein the two bifurcatable elements are self-bifurcatable in two opposing directions when the trabecular shunt is deployed from the delivery apparatus. The method may further comprise placing a delivery applicator inside a lumen of a hollow elongated tubular element, wherein the delivery applicator comprises a deployment mechanism for causing the two bifurcatable elements to move in two opposing directions.
  • The method may further comprise measuring and transmitting pressure of the anterior chamber of an eye, wherein the trabecular shunt comprises a pressure sensor for measuring and transmitting pressure. The means for measuring and transmitting pressure of an anterior chamber of an eye to an external receiver may be incorporated within a device that is placed inside the anterior chamber for sensing and transmitting the intraocular pressure. Any suitable micro pressure sensor or pressure sensor chip known to those of skill in the art may be utilized.
  • From the foregoing description, it should be appreciated that a novel device and methods for the surgical treatment of glaucoma have been disclosed for reducing intraocular pressure. While the invention has been described with reference to specific embodiments, the description is illustrative and is not to be construed as limiting the invention. Various modifications and applications of the invention may occur to those who are skilled in the art, without departing from the true spirit or scope of the invention. The breadth and scope of the invention should be defined only in accordance with the appended claims and their equivalents.

Claims (25)

  1. 1. The apparatus of claim 9, wherein the deployable portion comprises first and second members which project away from the outlet such that the members in the compacted position extend in substantially parallel directions.
  2. 2. The apparatus of claim 1, wherein the members in the expanded position extend in opposite directions.
  3. 3. The apparatus of claim 2, wherein the members comprise a shape-memory material, said members being biased toward the expanded position by the memory of the shape-memory material.
  4. 4. The apparatus of claim 3, wherein the shape-memory material has a shape transition temperature that is lower than a temperature to which the implant will be exposed when implanted.
  5. 5. The apparatus of claim 3, wherein the apparatus further comprises a delivery applicator for delivering the implant through eye tissue such that the members extend into the physiological outflow pathway, said applicator cooperating with the implant such that the members are in the compacted position prior to delivery through the eye tissue and in the expanded position subsequent to delivery into the physiological outflow pathway.
  6. 6. An implant, for treating glaucoma, comprising:
    an inflow portion configured to receive fluid from the anterior chamber of an eye;
    an outflow portion having an outflow opening and configured to deliver fluid from the inflow portion to Schlemm's canal of the eye through the outflow opening;
    wherein said outflow portion comprises a plurality of protrusions extending beyond the outflow portion in a direction substantially parallel to a long axis of the implant.
  7. 7. The implant of claim 6, wherein the protrusions are bendable or foldable outwardly into Schlemm's canal.
  8. 8. The implant of claim 6, wherein the protrusions comprise shape memory material an are adapted to extend in substantially opposite directions.
  9. 9. An apparatus for treating an ocular disorder comprising an implant, said implant comprising:
    a tubular member having an inlet configured to receive fluid from an anterior chamber of an eye, an outlet configured to deliver fluid from the inlet to a physiological outflow pathway of the eye, and a lumen therebetween configured for substantially free flow of said fluid and which generally defines a flow axis;
    a distal deployable portion at the outlet of the tubular member, the deployable portion having a compacted position configured to fit within a delivery device for transporting the implant and an expanded position configured to expand in the physiological outflow pathway of the eye;
    wherein the deployable portion moves transversely when transitioning between the compacted and expanded positions about a pivot axis which is substantially perpendicular to the flow axis.
  10. 10. The apparatus of claim 5, wherein the physiological outflow pathway comprises Schlemm's canal.
  11. 11. The apparatus of claim 9, wherein the deployable portion comprises two members which in the expanded position are outwardly deployed with one on either side of the tubular member.
  12. 12. The apparatus of claim 9, wherein the deployable portion comprises two members which in the expanded position are deployed in two substantially opposite directions relative to the tubular member.
  13. 13. The apparatus of claim 9, wherein the physiological outflow pathway comprises Schlemm's canal.
  14. 14. The apparatus of claim 9, wherein the deployable portion comprises a shape-memory material.
  15. 15. The apparatus of claim 14, wherein the deployable portion comprises two members which are biased from the compacted position to the expanded position by the memory of the shape-memory material.
  16. 16. The apparatus of claim 14, wherein the shape-memory material has a shape transition temperature that is lower than a temperature to which the implant will be exposed when implanted.
  17. 17. The apparatus of claim 9, wherein the apparatus further comprises said delivery device for transporting the implant from an incision in a cornea of the eye through the anterior chamber of the eye such that the inlet is positioned in the anterior chamber of the eye, the outlet is positioned in the physiological outflow pathway of the eye, and the deployable portion extends in the physiological outflow pathway of the eye.
  18. 18. The apparatus of claim 17, wherein the deployable portion comprises two deployable members.
  19. 19. The apparatus of claim 17, wherein the physiological outflow pathway comprises Schlemm's canal.
  20. 20. The apparatus of claim 9, wherein the apparatus further comprises said delivery device for delivering the implant through eye tissue adjacent the physiological outflow pathway of the eye.
  21. 21. The apparatus of claim 20, wherein the eye tissue comprises trabecular meshwork.
  22. 22. The apparatus of claim 20, wherein the physiological outflow pathway comprises Schlemm's canal.
  23. 23. The apparatus of claim 20, wherein said delivery device is configured to cooperate with the implant such that said deployable portion is in the compacted position prior to delivery into the eye tissue and in the expanded position subsequent to delivery into the physiological outflow pathway of the eye.
  24. 24. The apparatus of claim 23, wherein the eye tissue comprises trabecular meshwork and the physiological outflow pathway comprises Schlemm's canal.
  25. 25. The apparatus of claim 23, wherein the deployable portion comprises two deployable members.
US11121584 2001-05-02 2005-05-04 Ocular implants with deployable structure Abandoned US20090076436A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09847523 US6666841B2 (en) 2001-05-02 2001-05-02 Bifurcatable trabecular shunt for glaucoma treatment
US10626181 US6981958B1 (en) 2001-05-02 2003-07-24 Implant with pressure sensor for glaucoma treatment
US11121584 US20090076436A2 (en) 2001-05-02 2005-05-04 Ocular implants with deployable structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11121584 US20090076436A2 (en) 2001-05-02 2005-05-04 Ocular implants with deployable structure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10626181 Continuation US6981958B1 (en) 2001-05-02 2003-07-24 Implant with pressure sensor for glaucoma treatment

Publications (2)

Publication Number Publication Date
US20050192527A1 true US20050192527A1 (en) 2005-09-01
US20090076436A2 true true US20090076436A2 (en) 2009-03-19

Family

ID=34890607

Family Applications (3)

Application Number Title Priority Date Filing Date
US10626181 Active 2021-10-04 US6981958B1 (en) 2001-05-02 2003-07-24 Implant with pressure sensor for glaucoma treatment
US11121584 Abandoned US20090076436A2 (en) 2001-05-02 2005-05-04 Ocular implants with deployable structure
US11209563 Abandoned US20050288619A1 (en) 2001-05-02 2005-08-23 Biodegradable glaucoma implant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10626181 Active 2021-10-04 US6981958B1 (en) 2001-05-02 2003-07-24 Implant with pressure sensor for glaucoma treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11209563 Abandoned US20050288619A1 (en) 2001-05-02 2005-08-23 Biodegradable glaucoma implant

Country Status (1)

Country Link
US (3) US6981958B1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8109896B2 (en) 2008-02-11 2012-02-07 Optonol Ltd. Devices and methods for opening fluid passageways
US8313454B2 (en) 1997-11-20 2012-11-20 Optonol Ltd. Fluid drainage device, delivery device, and associated methods of use and manufacture
US9173775B2 (en) 2012-03-26 2015-11-03 Glaukos Corporation System for delivering multiple ocular implants
US9492320B2 (en) 1999-04-26 2016-11-15 Glaukos Corporation Shunt device and method for treating ocular disorders
US9572963B2 (en) 2001-04-07 2017-02-21 Glaukos Corporation Ocular disorder treatment methods and systems
US9993368B2 (en) 2000-04-14 2018-06-12 Glaukos Corporation System and method for treating an ocular disorder

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229469B1 (en) 1999-10-02 2007-06-12 Quantumcor, Inc. Methods for treating and repairing mitral valve annulus
US20050119737A1 (en) * 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040111050A1 (en) * 2000-04-14 2004-06-10 Gregory Smedley Implantable ocular pump to reduce intraocular pressure
US6962573B1 (en) 2000-10-18 2005-11-08 Wilcox Michael J C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US6881198B2 (en) * 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US9301875B2 (en) * 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US6981958B1 (en) * 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US7678065B2 (en) * 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
WO2002089699A9 (en) * 2001-05-03 2003-10-30 Glaukos Corp Medical device and methods of use for glaucoma treatment
US7067327B2 (en) * 2001-06-15 2006-06-27 The University Of Houston System Thin film optical detectors for retinal implantation and methods for making and using same
US7331984B2 (en) * 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
US7488303B1 (en) * 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
US20040225250A1 (en) 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
KR101050437B1 (en) * 2003-06-10 2011-07-19 카오 코퍼레이션 Method of producing a fatty acid with a fatty acid content - low transport
US7291125B2 (en) * 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
US7384550B2 (en) * 2004-02-24 2008-06-10 Becton, Dickinson And Company Glaucoma implant having MEMS filter module
US7226540B2 (en) * 2004-02-24 2007-06-05 Becton, Dickinson And Company MEMS filter module
US20060036207A1 (en) * 2004-02-24 2006-02-16 Koonmen James P System and method for treating glaucoma
US7364564B2 (en) * 2004-03-02 2008-04-29 Becton, Dickinson And Company Implant having MEMS flow module with movable, flow-controlling baffle
US20060173399A1 (en) * 2005-02-01 2006-08-03 Rodgers M S MEMS flow module with pivoting-type baffle
US20060206049A1 (en) * 2005-03-14 2006-09-14 Rodgers M S MEMS flow module with piston-type pressure regulating structure
US20060219627A1 (en) * 2005-03-31 2006-10-05 Rodgers M S MEMS filter module with concentric filtering walls
US7914569B2 (en) 2005-05-13 2011-03-29 Medtronics Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US7544176B2 (en) * 2005-06-21 2009-06-09 Becton, Dickinson And Company Glaucoma implant having MEMS flow module with flexing diaphragm for pressure regulation
CA2637656C (en) 2006-01-17 2016-06-28 Transcend Medical, Inc. Glaucoma treatment device
WO2007084582A3 (en) 2006-01-17 2007-12-21 Forsight Labs Llc Drug delivery treatment device
KR20110038144A (en) 2006-03-31 2011-04-13 큐엘티 플러그 딜리버리, 인코포레이티드 Drug delivery methods, structures, and compositions for nasolacrimal system
CA2655969C (en) * 2006-06-30 2014-11-25 Aquesys Inc. Methods, systems and apparatus for relieving pressure in an organ
US8834564B2 (en) 2006-09-19 2014-09-16 Medtronic, Inc. Sinus-engaging valve fixation member
US8876895B2 (en) 2006-09-19 2014-11-04 Medtronic Ventor Technologies Ltd. Valve fixation member having engagement arms
US8187266B2 (en) * 2006-09-29 2012-05-29 Quantumcor, Inc. Surgical probe and methods for targeted treatment of heart structures
US8090426B2 (en) * 2006-10-27 2012-01-03 Felder Robin A Microelectronic biosensor plug
WO2008061043A3 (en) 2006-11-10 2008-09-25 Glaukos Corp Uveoscleral shunt and methods for implanting same
US8894582B2 (en) 2007-01-26 2014-11-25 Endotronix, Inc. Cardiac pressure monitoring device
US10003862B2 (en) 2007-03-15 2018-06-19 Endotronix, Inc. Wireless sensor reader
US8493187B2 (en) 2007-03-15 2013-07-23 Endotronix, Inc. Wireless sensor reader
US20080281212A1 (en) * 2007-03-15 2008-11-13 Nunez Anthony I Transseptal monitoring device
US8570186B2 (en) 2011-04-25 2013-10-29 Endotronix, Inc. Wireless sensor reader
US8154389B2 (en) 2007-03-15 2012-04-10 Endotronix, Inc. Wireless sensor reader
US20080277332A1 (en) * 2007-05-11 2008-11-13 Becton, Dickinson And Company Micromachined membrane filter device for a glaucoma implant and method for making the same
JP5328788B2 (en) 2007-07-17 2013-10-30 トランセンド・メディカル・インコーポレイテッドTranscend Medical, Inc. Intraocular implant with enhanced capability of the hydrogel
CN101861135A (en) * 2007-09-07 2010-10-13 Qlt栓塞输送公司 Lacrimal implant detection
JP5524841B2 (en) 2007-09-07 2014-06-18 キュー エル ティー インク.QLT Inc. Lacrimal implants and related methods
DK2207529T3 (en) 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
US8734377B2 (en) 2007-09-24 2014-05-27 Ivantis, Inc. Ocular implants with asymmetric flexibility
US7740604B2 (en) * 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
US20090082862A1 (en) 2007-09-24 2009-03-26 Schieber Andrew T Ocular Implant Architectures
US8808222B2 (en) 2007-11-20 2014-08-19 Ivantis, Inc. Methods and apparatus for delivering ocular implants into the eye
US8512404B2 (en) * 2007-11-20 2013-08-20 Ivantis, Inc. Ocular implant delivery system and method
CN101965211A (en) 2008-03-05 2011-02-02 伊万提斯公司 Methods and apparatus for treating glaucoma
US20110082385A1 (en) * 2008-04-17 2011-04-07 Yale University Method for implanting intraocular pressure sensor
WO2009158524A3 (en) * 2008-06-25 2010-03-11 Transcend Medical, Inc. Ocular implant with shape change capabilities
CN102238926B (en) * 2008-12-05 2015-09-16 伊万提斯公司 The ocular implant for delivery to a method and apparatus eye
WO2010072574A1 (en) * 2008-12-22 2010-07-01 Grieshaber Ophthalmic Research Foundaton Implant for inserting into the schlemm's canal of an eye
JP5524983B2 (en) 2009-01-28 2014-06-18 トランセンド・メディカル・インコーポレイテッドTranscend Medical, Inc. Implant system
EP2451375B1 (en) * 2009-07-09 2018-10-03 Ivantis, Inc. Single operator device for delivering an ocular implant
CN102481404B (en) * 2009-07-09 2014-03-05 伊万提斯公司 Ocular implants
WO2011050360A1 (en) 2009-10-23 2011-04-28 Ivantis, Inc. Ocular implant system and method
US20110105990A1 (en) * 2009-11-04 2011-05-05 Silvestrini Thomas A Zonal drug delivery device and method
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8652204B2 (en) 2010-04-01 2014-02-18 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US8545430B2 (en) 2010-06-09 2013-10-01 Transcend Medical, Inc. Expandable ocular devices
WO2011163505A1 (en) 2010-06-23 2011-12-29 Ivantis, Inc. Ocular implants deployed in schlemm's canal of the eye
US8828070B2 (en) 2010-11-15 2014-09-09 Aquesys, Inc. Devices for deploying intraocular shunts
US8974511B2 (en) 2010-11-15 2015-03-10 Aquesys, Inc. Methods for treating closed angle glaucoma
US8721702B2 (en) 2010-11-15 2014-05-13 Aquesys, Inc. Intraocular shunt deployment devices
US8585629B2 (en) 2010-11-15 2013-11-19 Aquesys, Inc. Systems for deploying intraocular shunts
US8852256B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for intraocular shunt placement
US20120123316A1 (en) 2010-11-15 2012-05-17 Aquesys, Inc. Intraocular shunts for placement in the intra-tenon's space
US9095411B2 (en) 2010-11-15 2015-08-04 Aquesys, Inc. Devices for deploying intraocular shunts
US8758290B2 (en) 2010-11-15 2014-06-24 Aquesys, Inc. Devices and methods for implanting a shunt in the suprachoroidal space
US20120165720A1 (en) * 2010-11-15 2012-06-28 Aquesys, Inc. Intraocular shunts
US8852137B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for implanting a soft gel shunt in the suprachoroidal space
US8308701B2 (en) 2010-11-15 2012-11-13 Aquesys, Inc. Methods for deploying intraocular shunts
US8801766B2 (en) 2010-11-15 2014-08-12 Aquesys, Inc. Devices for deploying intraocular shunts
US8663303B2 (en) 2010-11-15 2014-03-04 Aquesys, Inc. Methods for deploying an intraocular shunt from a deployment device and into an eye
CN103476371B (en) 2011-02-23 2015-12-16 格里沙贝眼科研究基金会 Implant for the treatment of glaucoma
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
EP2734261B1 (en) * 2011-07-18 2018-02-21 Mor-Research Applications Ltd. A device for adjusting the intraocular pressure
EP3120834A1 (en) 2011-08-29 2017-01-25 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
WO2013040079A1 (en) 2011-09-13 2013-03-21 Dose Medical Corporation Intraocular physiological sensor
US8883189B2 (en) 2011-09-27 2014-11-11 The Regents Of The University Of Colorado, A Body Corporate Intraocular encapsulation of oxygenic bacteria
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US8852136B2 (en) 2011-12-08 2014-10-07 Aquesys, Inc. Methods for placing a shunt into the intra-scleral space
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US8894603B2 (en) 2012-03-20 2014-11-25 Sight Sciences, Inc. Ocular delivery systems and methods
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
US20140066833A1 (en) * 2012-08-28 2014-03-06 Clearlix Ltd. Expandable fluid drainage implants and associated delivery devices and methods
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US9610195B2 (en) 2013-02-27 2017-04-04 Aquesys, Inc. Intraocular shunt implantation methods and devices
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US20150057583A1 (en) * 2013-08-24 2015-02-26 Alcon Research, Ltd. Trabecular meshwork stimulation device
KR20150034010A (en) * 2013-09-25 2015-04-02 사회복지법인 삼성생명공익재단 An Apparatus for Treating Ocular Diseases Induced by Increased Intraocular Pressure
US9996712B2 (en) 2015-09-02 2018-06-12 Endotronix, Inc. Self test device and method for wireless sensor reader
WO2017106517A1 (en) * 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system

Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788327A (en) * 1971-03-30 1974-01-29 H Donowitz Surgical implant device
US4428746A (en) * 1981-07-29 1984-01-31 Antonio Mendez Glaucoma treatment device
US4501274A (en) * 1981-03-12 1985-02-26 Finn Skjaerpe Microsurgical instrument
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4583224A (en) * 1982-11-08 1986-04-15 Hitachi, Ltd. Fault tolerable redundancy control
US4634418A (en) * 1984-04-06 1987-01-06 Binder Perry S Hydrogel seton
US4718907A (en) * 1985-06-20 1988-01-12 Atrium Medical Corporation Vascular prosthesis having fluorinated coating with varying F/C ratio
US4722724A (en) * 1986-06-23 1988-02-02 Stanley Schocket Anterior chamber tube shunt to an encircling band, and related surgical procedure
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4750901A (en) * 1986-03-07 1988-06-14 Molteno Anthony C B Implant for drainage of aqueous humour
US4804382A (en) * 1986-06-02 1989-02-14 Sulzer Brothers Limited Artificial vessel
US4820626A (en) * 1985-06-06 1989-04-11 Thomas Jefferson University Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself
US4900300A (en) * 1987-07-06 1990-02-13 Lee David A Surgical instrument
US4936825A (en) * 1988-04-11 1990-06-26 Ungerleider Bruce A Method for reducing intraocular pressure caused by glaucoma
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5005577A (en) * 1988-08-23 1991-04-09 Frenkel Ronald E P Intraocular lens pressure monitoring device
US5092837A (en) * 1989-12-20 1992-03-03 Robert Ritch Method for the treatment of glaucoma
US5095887A (en) * 1989-09-12 1992-03-17 Claude Leon Microscope-endoscope assembly especially usable in surgery
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5180362A (en) * 1990-04-03 1993-01-19 Worst J G F Gonio seton
US5207685A (en) * 1992-02-11 1993-05-04 Cinberg James Z Tympanic ventilation tube and related technique
US5290295A (en) * 1992-07-15 1994-03-01 Querals & Fine, Inc. Insertion tool for an intraluminal graft procedure
US5318513A (en) * 1992-09-24 1994-06-07 Leib Martin L Canalicular balloon fixation stent
US5397300A (en) * 1990-05-31 1995-03-14 Iovision, Inc. Glaucoma implant
US5486165A (en) * 1992-01-10 1996-01-23 Stegmann; Robert Method and appliance for maintaining the natural intraocular pressure
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5520631A (en) * 1994-07-22 1996-05-28 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US5601549A (en) * 1994-11-17 1997-02-11 Machida Endoscope Co., Ltd. Medical observing instrument
US5601094A (en) * 1994-11-22 1997-02-11 Reiss; George R. Ophthalmic shunt
US5626559A (en) * 1994-05-02 1997-05-06 Ramot University Authority For Applied Research And Industrial Development Ltd. Ophthalmic device for draining excess intraocular fluid
US5626558A (en) * 1995-05-05 1997-05-06 Suson; John Adjustable flow rate glaucoma shunt and method of using same
US5630020A (en) * 1989-06-09 1997-05-13 U.S. Philips Corporation Learning method and neural network structure
US5639278A (en) * 1993-10-21 1997-06-17 Corvita Corporation Expandable supportive bifurcated endoluminal grafts
US5704907A (en) * 1994-07-22 1998-01-06 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US5713844A (en) * 1997-01-10 1998-02-03 Peyman; Gholam A. Device and method for regulating intraocular pressure
US5723005A (en) * 1995-06-07 1998-03-03 Herrick Family Limited Partnership Punctum plug having a collapsible flared section and method
US5741333A (en) * 1995-04-12 1998-04-21 Corvita Corporation Self-expanding stent for a medical device to be introduced into a cavity of a body
US5743868A (en) * 1994-02-14 1998-04-28 Brown; Reay H. Corneal pressure-regulating implant device
US5752928A (en) * 1997-07-14 1998-05-19 Rdo Medical, Inc. Glaucoma pressure regulator
US5766242A (en) * 1993-11-15 1998-06-16 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5766243A (en) * 1995-08-21 1998-06-16 Oasis Medical, Inc. Abrasive polished canalicular implant
US5865831A (en) * 1996-04-17 1999-02-02 Premier Laser Systems, Inc. Laser surgical procedures for treatment of glaucoma
US5868697A (en) * 1995-05-14 1999-02-09 Optonol Ltd. Intraocular implant
US5879319A (en) * 1994-06-22 1999-03-09 Chauvin Opsia Sclerotomy implant
US5882327A (en) * 1997-04-17 1999-03-16 Jacob; Jean T. Long-term glaucoma drainage implant
US5886822A (en) * 1996-10-08 1999-03-23 The Microoptical Corporation Image combining system for eyeglasses and face masks
US5908449A (en) * 1994-04-29 1999-06-01 W. L. Gore & Associates, Inc. Blood contact surfaces using extracellular matrix synthesized in vitro
US6033434A (en) * 1995-06-08 2000-03-07 Ave Galway Limited Bifurcated endovascular stent and methods for forming and placing
US6045557A (en) * 1995-11-10 2000-04-04 Baxter International Inc. Delivery catheter and method for positioning an intraluminal graft
US6050999A (en) * 1997-12-18 2000-04-18 Keravision, Inc. Corneal implant introducer and method of use
US6050970A (en) * 1997-05-08 2000-04-18 Pharmacia & Upjohn Company Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye
US6059772A (en) * 1995-03-10 2000-05-09 Candela Corporation Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US6059812A (en) * 1997-03-21 2000-05-09 Schneider (Usa) Inc. Self-expanding medical device for centering radioactive treatment sources in body vessels
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6071286A (en) * 1997-02-19 2000-06-06 Mawad; Michel E. Combination angioplasty balloon/stent deployment device
US6074305A (en) * 1999-03-24 2000-06-13 Schnapp; Abraham Implement for playing, walking and training
US6077299A (en) * 1998-06-22 2000-06-20 Eyetronic, Llc Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma
US6168575B1 (en) * 1998-01-29 2001-01-02 David Pyam Soltanpour Method and apparatus for controlling intraocular pressure
US6187016B1 (en) * 1999-09-14 2001-02-13 Daniel G. Hedges Stent retrieval device
US6193656B1 (en) * 1999-02-08 2001-02-27 Robert E. Jeffries Intraocular pressure monitoring/measuring apparatus and method
US6197056B1 (en) * 1992-07-15 2001-03-06 Ras Holding Corp. Segmented scleral band for treatment of presbyopia and other eye disorders
US6203513B1 (en) * 1997-11-20 2001-03-20 Optonol Ltd. Flow regulating implant, method of manufacture, and delivery device
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6228873B1 (en) * 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6231597B1 (en) * 1999-02-16 2001-05-15 Mark E. Deem Apparatus and methods for selectively stenting a portion of a vessel wall
US6241721B1 (en) * 1998-10-09 2001-06-05 Colette Cozean Laser surgical procedures for treatment of glaucoma
US6251090B1 (en) * 1994-12-12 2001-06-26 Robert Logan Avery Intravitreal medicine delivery
US6342058B1 (en) * 1999-05-14 2002-01-29 Valdemar Portney Iris fixated intraocular lens and instrument for attaching same to an iris
US20020013546A1 (en) * 1997-08-15 2002-01-31 Grieshaber & Co. Ag Schaffhausen Method and device to improve aqueous humor drainage in an eye
US20020013572A1 (en) * 2000-05-19 2002-01-31 Berlin Michael S. Delivery system and method of use for the eye
US6348042B1 (en) * 1999-02-02 2002-02-19 W. Lee Warren, Jr. Bioactive shunt
US20020026200A1 (en) * 2000-08-22 2002-02-28 Savage James A. Method and apparatus for treatment of glaucoma
US6375642B1 (en) * 2000-02-15 2002-04-23 Grieshaber & Co. Ag Schaffhausen Method of and device for improving a drainage of aqueous humor within the eye
US20020072673A1 (en) * 1999-12-10 2002-06-13 Yamamoto Ronald K. Treatment of ocular disease
US6524275B1 (en) * 1999-04-26 2003-02-25 Gmp Vision Solutions, Inc. Inflatable device and method for treating glaucoma
US6530896B1 (en) * 1996-05-13 2003-03-11 James B. Elliott Apparatus and method for introducing an implant
US6533768B1 (en) * 2000-04-14 2003-03-18 The Regents Of The University Of California Device for glaucoma treatment and methods thereof
US20030055372A1 (en) * 1999-04-26 2003-03-20 Lynch Mary G. Shunt device and method for treating glaucoma
US20030060752A1 (en) * 2000-04-14 2003-03-27 Olav Bergheim Glaucoma device and methods thereof
US6544249B1 (en) * 1996-11-29 2003-04-08 The Lions Eye Institute Of Western Australia Incorporated Biological microfistula tube and implantation method and apparatus
US20030088260A1 (en) * 2001-11-08 2003-05-08 Smedley Gregory T. Combined treatment for cataract and glaucoma treatment
US20030097151A1 (en) * 2001-10-25 2003-05-22 Smedley Gregory T. Apparatus and mitochondrial treatment for glaucoma
US6579235B1 (en) * 1999-11-01 2003-06-17 The Johns Hopkins University Method for monitoring intraocular pressure using a passive intraocular pressure sensor and patient worn monitoring recorder
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
US20040050392A1 (en) * 2001-08-28 2004-03-18 Hosheng Tu Glaucoma stent for treating glaucoma and methods of use
US6726676B2 (en) * 2000-01-05 2004-04-27 Grieshaber & Co. Ag Schaffhausen Method of and device for improving the flow of aqueous humor within the eye
US6730056B1 (en) * 2000-09-21 2004-05-04 Motorola, Inc. Eye implant for treating glaucoma and method for manufacturing same
USD490152S1 (en) * 2003-02-28 2004-05-18 Glaukos Corporation Surgical handpiece
US6736791B1 (en) * 2000-04-14 2004-05-18 Glaukos Corporation Glaucoma treatment device
US20040102729A1 (en) * 2002-04-08 2004-05-27 David Haffner Devices and methods for glaucoma treatment
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US6881198B2 (en) * 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
US6981958B1 (en) * 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US7033603B2 (en) * 1999-08-06 2006-04-25 Board Of Regents The University Of Texas Drug releasing biodegradable fiber for delivery of therapeutics

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4037604A (en) 1976-01-05 1977-07-26 Newkirk John B Artifical biological drainage device
US4168697A (en) 1977-01-17 1979-09-25 Cantekin Erdem I Middle ear ventilating tube and method
US4175563A (en) 1977-10-05 1979-11-27 Arenberg Irving K Biological drainage shunt
US4402681A (en) 1980-08-23 1983-09-06 Haas Joseph S Artificial implant valve for the regulation of intraocular pressure
US4554918A (en) 1982-07-28 1985-11-26 White Thomas C Ocular pressure relief device
US4787885A (en) 1984-04-06 1988-11-29 Binder Perry S Hydrogel seton
US4604087A (en) 1985-02-26 1986-08-05 Joseph Neil H Aqueous humor drainage device
US4632842A (en) 1985-06-20 1986-12-30 Atrium Medical Corporation Glow discharge process for producing implantable devices
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4846172A (en) 1987-05-26 1989-07-11 Berlin Michael S Laser-delivery eye-treatment method
US4886488A (en) 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method
US5785674A (en) 1988-10-07 1998-07-28 Mateen; Ahmed Abdul Device and method for treating glaucoma
US5681275A (en) 1988-10-07 1997-10-28 Ahmed; Abdul Mateen Ophthalmological device with adaptable multiple distribution plates
US4946436A (en) 1989-11-17 1990-08-07 Smith Stewart G Pressure-relieving device and process for implanting
USRE35390E (en) 1989-11-17 1996-12-03 Smith; Stewart G. Pressure relieving device and process for implanting
US4968296A (en) 1989-12-20 1990-11-06 Robert Ritch Transscleral drainage implant device for the treatment of glaucoma
US5073163A (en) 1990-01-29 1991-12-17 Lippman Myron E Apparatus for treating glaucoma
US5129895A (en) 1990-05-16 1992-07-14 Sunrise Technologies, Inc. Laser sclerostomy procedure
US5127901A (en) 1990-05-18 1992-07-07 Odrich Ronald B Implant with subconjunctival arch
US5041081A (en) 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5476445A (en) 1990-05-31 1995-12-19 Iovision, Inc. Glaucoma implant with a temporary flow restricting seal
US5454796A (en) 1991-04-09 1995-10-03 Hood Laboratories Device and method for controlling intraocular fluid pressure
US5312394A (en) 1991-04-29 1994-05-17 Hugh Beckman Apparatus and method for surgically performing a filtering operation on an eye for glaucoma
US5246451A (en) 1991-04-30 1993-09-21 Medtronic, Inc. Vascular prosthesis and method
US6007511A (en) 1991-05-08 1999-12-28 Prywes; Arnold S. Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation
US5300020A (en) 1991-05-31 1994-04-05 Medflex Corporation Surgically implantable device for glaucoma relief
US5171213A (en) 1991-08-14 1992-12-15 Price Jr Francis W Technique for fistulization of the eye and an eye filtration prosthesis useful therefor
US5334137A (en) 1992-02-21 1994-08-02 Eagle Vision, Inc. Lacrimal fluid control device
US5346464A (en) 1992-03-10 1994-09-13 Camras Carl B Method and apparatus for reducing intraocular pressure
US5370641A (en) 1992-05-22 1994-12-06 O'donnell, Jr.; Francis E. Laser trabeculodissection
DE4219299C2 (en) 1992-06-12 1994-03-24 Leica Mikroskopie & Syst microscope
US5370607A (en) 1992-10-28 1994-12-06 Annuit Coeptis, Inc. Glaucoma implant device and method for implanting same
US5338291A (en) 1993-02-03 1994-08-16 Pudenz-Schulte Medical Research Corporation Glaucoma shunt and method for draining aqueous humor
US5342370A (en) 1993-03-19 1994-08-30 University Of Miami Method and apparatus for implanting an artifical meshwork in glaucoma surgery
EP0626153A1 (en) 1993-05-28 1994-11-30 Medical Shape Memory, Ltd. Ni-Ti medical stent
US5735892A (en) 1993-08-18 1998-04-07 W. L. Gore & Associates, Inc. Intraluminal stent graft
US5665114A (en) 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5702419A (en) 1994-09-21 1997-12-30 Wake Forest University Expandable, intraluminal stents
US5433701A (en) 1994-12-21 1995-07-18 Rubinstein; Mark H. Apparatus for reducing ocular pressure
US5558630A (en) 1994-12-30 1996-09-24 Fisher; Bret L. Intrascleral implant and method for the regulation of intraocular pressure
JPH10513455A (en) 1995-02-10 1998-12-22 ザ ユニバーシティ オブ トロント イノベーションズ ファウンデーション Deprenyl compounds for the treatment of glaucoma
EP0957949B1 (en) 1995-05-14 2004-08-04 Optonol Ltd. Intraocular implant, delivery device, and method of implantation
US5968058A (en) 1996-03-27 1999-10-19 Optonol Ltd. Device for and method of implanting an intraocular implant
US5836939A (en) 1995-10-25 1998-11-17 Plc Medical Systems, Inc. Surgical laser handpiece
US5651783A (en) 1995-12-20 1997-07-29 Reynard; Michael Fiber optic sleeve for surgical instruments
US5807302A (en) 1996-04-01 1998-09-15 Wandel; Thaddeus Treatment of glaucoma
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5670161A (en) 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
US5830139A (en) 1996-09-04 1998-11-03 Abreu; Marcio M. Tonometer system for measuring intraocular pressure by applanation and/or indentation
US6007510A (en) 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5893837A (en) 1997-02-28 1999-04-13 Staar Surgical Company, Inc. Glaucoma drain implanting device and method
US5830171A (en) 1997-08-12 1998-11-03 Odyssey Medical, Inc. Punctal occluder
US6004302A (en) 1997-08-28 1999-12-21 Brierley; Lawrence A. Cannula
US6605053B1 (en) * 1999-09-10 2003-08-12 Percardia, Inc. Conduit designs and related methods for optimal flow control
US6666841B2 (en) * 2001-05-02 2003-12-23 Glaukos Corporation Bifurcatable trabecular shunt for glaucoma treatment

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788327A (en) * 1971-03-30 1974-01-29 H Donowitz Surgical implant device
US4501274A (en) * 1981-03-12 1985-02-26 Finn Skjaerpe Microsurgical instrument
US4428746A (en) * 1981-07-29 1984-01-31 Antonio Mendez Glaucoma treatment device
US4583224A (en) * 1982-11-08 1986-04-15 Hitachi, Ltd. Fault tolerable redundancy control
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4634418A (en) * 1984-04-06 1987-01-06 Binder Perry S Hydrogel seton
US4820626A (en) * 1985-06-06 1989-04-11 Thomas Jefferson University Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself
US4718907A (en) * 1985-06-20 1988-01-12 Atrium Medical Corporation Vascular prosthesis having fluorinated coating with varying F/C ratio
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4750901A (en) * 1986-03-07 1988-06-14 Molteno Anthony C B Implant for drainage of aqueous humour
US4804382A (en) * 1986-06-02 1989-02-14 Sulzer Brothers Limited Artificial vessel
US4722724A (en) * 1986-06-23 1988-02-02 Stanley Schocket Anterior chamber tube shunt to an encircling band, and related surgical procedure
US4900300A (en) * 1987-07-06 1990-02-13 Lee David A Surgical instrument
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4936825A (en) * 1988-04-11 1990-06-26 Ungerleider Bruce A Method for reducing intraocular pressure caused by glaucoma
US5005577A (en) * 1988-08-23 1991-04-09 Frenkel Ronald E P Intraocular lens pressure monitoring device
US5630020A (en) * 1989-06-09 1997-05-13 U.S. Philips Corporation Learning method and neural network structure
US5095887A (en) * 1989-09-12 1992-03-17 Claude Leon Microscope-endoscope assembly especially usable in surgery
US5092837A (en) * 1989-12-20 1992-03-03 Robert Ritch Method for the treatment of glaucoma
US5180362A (en) * 1990-04-03 1993-01-19 Worst J G F Gonio seton
US5397300A (en) * 1990-05-31 1995-03-14 Iovision, Inc. Glaucoma implant
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5486165A (en) * 1992-01-10 1996-01-23 Stegmann; Robert Method and appliance for maintaining the natural intraocular pressure
US5207685A (en) * 1992-02-11 1993-05-04 Cinberg James Z Tympanic ventilation tube and related technique
US5290295A (en) * 1992-07-15 1994-03-01 Querals & Fine, Inc. Insertion tool for an intraluminal graft procedure
US6197056B1 (en) * 1992-07-15 2001-03-06 Ras Holding Corp. Segmented scleral band for treatment of presbyopia and other eye disorders
US5318513A (en) * 1992-09-24 1994-06-07 Leib Martin L Canalicular balloon fixation stent
US5639278A (en) * 1993-10-21 1997-06-17 Corvita Corporation Expandable supportive bifurcated endoluminal grafts
US5766242A (en) * 1993-11-15 1998-06-16 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5743868A (en) * 1994-02-14 1998-04-28 Brown; Reay H. Corneal pressure-regulating implant device
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5908449A (en) * 1994-04-29 1999-06-01 W. L. Gore & Associates, Inc. Blood contact surfaces using extracellular matrix synthesized in vitro
US5626559A (en) * 1994-05-02 1997-05-06 Ramot University Authority For Applied Research And Industrial Development Ltd. Ophthalmic device for draining excess intraocular fluid
US5879319A (en) * 1994-06-22 1999-03-09 Chauvin Opsia Sclerotomy implant
US5704907A (en) * 1994-07-22 1998-01-06 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US5520631A (en) * 1994-07-22 1996-05-28 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5601549A (en) * 1994-11-17 1997-02-11 Machida Endoscope Co., Ltd. Medical observing instrument
US5601094A (en) * 1994-11-22 1997-02-11 Reiss; George R. Ophthalmic shunt
US6228873B1 (en) * 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6251090B1 (en) * 1994-12-12 2001-06-26 Robert Logan Avery Intravitreal medicine delivery
US6059772A (en) * 1995-03-10 2000-05-09 Candela Corporation Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US5741333A (en) * 1995-04-12 1998-04-21 Corvita Corporation Self-expanding stent for a medical device to be introduced into a cavity of a body
US5626558A (en) * 1995-05-05 1997-05-06 Suson; John Adjustable flow rate glaucoma shunt and method of using same
US5868697A (en) * 1995-05-14 1999-02-09 Optonol Ltd. Intraocular implant
US5723005A (en) * 1995-06-07 1998-03-03 Herrick Family Limited Partnership Punctum plug having a collapsible flared section and method
US6033434A (en) * 1995-06-08 2000-03-07 Ave Galway Limited Bifurcated endovascular stent and methods for forming and placing
US5766243A (en) * 1995-08-21 1998-06-16 Oasis Medical, Inc. Abrasive polished canalicular implant
US6045557A (en) * 1995-11-10 2000-04-04 Baxter International Inc. Delivery catheter and method for positioning an intraluminal graft
US5865831A (en) * 1996-04-17 1999-02-02 Premier Laser Systems, Inc. Laser surgical procedures for treatment of glaucoma
US6530896B1 (en) * 1996-05-13 2003-03-11 James B. Elliott Apparatus and method for introducing an implant
US5886822A (en) * 1996-10-08 1999-03-23 The Microoptical Corporation Image combining system for eyeglasses and face masks
US6544249B1 (en) * 1996-11-29 2003-04-08 The Lions Eye Institute Of Western Australia Incorporated Biological microfistula tube and implantation method and apparatus
US5713844A (en) * 1997-01-10 1998-02-03 Peyman; Gholam A. Device and method for regulating intraocular pressure
US6071286A (en) * 1997-02-19 2000-06-06 Mawad; Michel E. Combination angioplasty balloon/stent deployment device
US6059812A (en) * 1997-03-21 2000-05-09 Schneider (Usa) Inc. Self-expanding medical device for centering radioactive treatment sources in body vessels
US5882327A (en) * 1997-04-17 1999-03-16 Jacob; Jean T. Long-term glaucoma drainage implant
US6050970A (en) * 1997-05-08 2000-04-18 Pharmacia & Upjohn Company Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye
US5752928A (en) * 1997-07-14 1998-05-19 Rdo Medical, Inc. Glaucoma pressure regulator
US20020013546A1 (en) * 1997-08-15 2002-01-31 Grieshaber & Co. Ag Schaffhausen Method and device to improve aqueous humor drainage in an eye
US6203513B1 (en) * 1997-11-20 2001-03-20 Optonol Ltd. Flow regulating implant, method of manufacture, and delivery device
US6050999A (en) * 1997-12-18 2000-04-18 Keravision, Inc. Corneal implant introducer and method of use
US6168575B1 (en) * 1998-01-29 2001-01-02 David Pyam Soltanpour Method and apparatus for controlling intraocular pressure
US6077299A (en) * 1998-06-22 2000-06-20 Eyetronic, Llc Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma
US6241721B1 (en) * 1998-10-09 2001-06-05 Colette Cozean Laser surgical procedures for treatment of glaucoma
US6348042B1 (en) * 1999-02-02 2002-02-19 W. Lee Warren, Jr. Bioactive shunt
US6193656B1 (en) * 1999-02-08 2001-02-27 Robert E. Jeffries Intraocular pressure monitoring/measuring apparatus and method
US6231597B1 (en) * 1999-02-16 2001-05-15 Mark E. Deem Apparatus and methods for selectively stenting a portion of a vessel wall
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6548078B2 (en) * 1999-03-22 2003-04-15 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6074305A (en) * 1999-03-24 2000-06-13 Schnapp; Abraham Implement for playing, walking and training
US20050038334A1 (en) * 1999-04-26 2005-02-17 Lynch Mary G. Shunt device and method for treating glaucoma
US20030069637A1 (en) * 1999-04-26 2003-04-10 Lynch Mary G. Stent device and method for treating glaucoma
US6524275B1 (en) * 1999-04-26 2003-02-25 Gmp Vision Solutions, Inc. Inflatable device and method for treating glaucoma
US20030055372A1 (en) * 1999-04-26 2003-03-20 Lynch Mary G. Shunt device and method for treating glaucoma
US6342058B1 (en) * 1999-05-14 2002-01-29 Valdemar Portney Iris fixated intraocular lens and instrument for attaching same to an iris
US7033603B2 (en) * 1999-08-06 2006-04-25 Board Of Regents The University Of Texas Drug releasing biodegradable fiber for delivery of therapeutics
US6187016B1 (en) * 1999-09-14 2001-02-13 Daniel G. Hedges Stent retrieval device
US6579235B1 (en) * 1999-11-01 2003-06-17 The Johns Hopkins University Method for monitoring intraocular pressure using a passive intraocular pressure sensor and patient worn monitoring recorder
US20020072673A1 (en) * 1999-12-10 2002-06-13 Yamamoto Ronald K. Treatment of ocular disease
US6726676B2 (en) * 2000-01-05 2004-04-27 Grieshaber & Co. Ag Schaffhausen Method of and device for improving the flow of aqueous humor within the eye
US6375642B1 (en) * 2000-02-15 2002-04-23 Grieshaber & Co. Ag Schaffhausen Method of and device for improving a drainage of aqueous humor within the eye
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US6533768B1 (en) * 2000-04-14 2003-03-18 The Regents Of The University Of California Device for glaucoma treatment and methods thereof
US6736791B1 (en) * 2000-04-14 2004-05-18 Glaukos Corporation Glaucoma treatment device
US20030060752A1 (en) * 2000-04-14 2003-03-27 Olav Bergheim Glaucoma device and methods thereof
US20020013572A1 (en) * 2000-05-19 2002-01-31 Berlin Michael S. Delivery system and method of use for the eye
US6699211B2 (en) * 2000-08-22 2004-03-02 James A. Savage Method and apparatus for treatment of glaucoma
US20020026200A1 (en) * 2000-08-22 2002-02-28 Savage James A. Method and apparatus for treatment of glaucoma
US6730056B1 (en) * 2000-09-21 2004-05-04 Motorola, Inc. Eye implant for treating glaucoma and method for manufacturing same
US6881198B2 (en) * 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
US6981958B1 (en) * 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US20040050392A1 (en) * 2001-08-28 2004-03-18 Hosheng Tu Glaucoma stent for treating glaucoma and methods of use
US20030097151A1 (en) * 2001-10-25 2003-05-22 Smedley Gregory T. Apparatus and mitochondrial treatment for glaucoma
US20030088260A1 (en) * 2001-11-08 2003-05-08 Smedley Gregory T. Combined treatment for cataract and glaucoma treatment
US20040102729A1 (en) * 2002-04-08 2004-05-27 David Haffner Devices and methods for glaucoma treatment
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
USD490152S1 (en) * 2003-02-28 2004-05-18 Glaukos Corporation Surgical handpiece

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8313454B2 (en) 1997-11-20 2012-11-20 Optonol Ltd. Fluid drainage device, delivery device, and associated methods of use and manufacture
US9492320B2 (en) 1999-04-26 2016-11-15 Glaukos Corporation Shunt device and method for treating ocular disorders
US9827143B2 (en) 1999-04-26 2017-11-28 Glaukos Corporation Shunt device and method for treating ocular disorders
US9993368B2 (en) 2000-04-14 2018-06-12 Glaukos Corporation System and method for treating an ocular disorder
US9572963B2 (en) 2001-04-07 2017-02-21 Glaukos Corporation Ocular disorder treatment methods and systems
US9987472B2 (en) 2001-04-07 2018-06-05 Glaukos Corporation Ocular implant delivery systems
US8109896B2 (en) 2008-02-11 2012-02-07 Optonol Ltd. Devices and methods for opening fluid passageways
US9173774B2 (en) 2010-03-26 2015-11-03 Optonol Ltd. Fluid drainage device, delivery device, and associated methods of use and manufacture
US9554940B2 (en) 2012-03-26 2017-01-31 Glaukos Corporation System and method for delivering multiple ocular implants
US9173775B2 (en) 2012-03-26 2015-11-03 Glaukos Corporation System for delivering multiple ocular implants

Also Published As

Publication number Publication date Type
US20050288619A1 (en) 2005-12-29 application
US20050192527A1 (en) 2005-09-01 application
US6981958B1 (en) 2006-01-03 grant

Similar Documents

Publication Publication Date Title
Krasnov Externalization of Schlemm's canal (sinusotomy) in glaucoma.
US6464724B1 (en) Stent device and method for treating glaucoma
US5342370A (en) Method and apparatus for implanting an artifical meshwork in glaucoma surgery
US7220238B2 (en) Shunt device and method for treating glaucoma
US6508779B1 (en) Adjustable flow rate glaucoma shunt and method of using same
US4604087A (en) Aqueous humor drainage device
US4037604A (en) Artifical biological drainage device
US20050283108A1 (en) Apparatus and method for non-pharmacological treatment of glaucoma and lowering intraocular pressure
US20100191103A1 (en) Apparatus and method for surgical bypass of aqueous humor
US8425449B2 (en) Ocular implants and methods for delivering ocular implants into the eye
US20030236483A1 (en) Dual drainage ocular shunt for glaucoma
US20120123317A1 (en) Methods for implanation of glaucoma shunts
US20030097151A1 (en) Apparatus and mitochondrial treatment for glaucoma
US20060173446A1 (en) Surgical apparatus
US20040254520A1 (en) Coil implant for glaucoma treatment
US6203513B1 (en) Flow regulating implant, method of manufacture, and delivery device
US20100010416A1 (en) Glaucoma treatment device
US4886488A (en) Glaucoma drainage the lacrimal system and method
US20060155238A1 (en) Uveoscleral drainage device
US7708711B2 (en) Ocular implant with therapeutic agents and methods thereof
US20110118835A1 (en) Branched ocular implant
US20120310137A1 (en) Eye shunt with porous structure
US20080306429A1 (en) Uveoscleral drainage device
US20090082860A1 (en) Ocular Implants with Asymmetric Flexibility
US20040111050A1 (en) Implantable ocular pump to reduce intraocular pressure